🔥Telegram İfşa

Really great to see Thoracic Sub-Study of our SARON study presented at #ESTRO25 Simultaneous delivery of CFRT to primary (+/- nodes) & SABR to thoracic mets in synchronous OM-NSCLC ➡️Acceptable acute RT-related adverse events ➡️No grade >3 adverse events observed

Most viewed this week from JAMA Oncology: Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/4mlAy6q

Happy to co author this work which looks at patient selection and outcomes following local treatments for lung mets. Check it out! Open access

👀 #radonc - ☢️Should we be thinking of timing of #radiotherapy as a factor? Gerry Hanna Drew Moghanaki Henning Willers, MD, FASTRO Søren M Bentzen Ralph Weichselbaum

EXTEND showed us that MDT + ADT > ADT RADIOSA showed MDT + ADT > MDT. STORM / PEACE-V showed ENI + MDT + ADT > MDT + ADT All studies had some novel imaging defined mHSPC (STORM was 100% novel) Can we just accept that MDT (+/- elective RT) + ADT is better than either?!?

It is most gratifying to see talented young physicians successfully complete their residency/fellowship training. Congratulations to our new graduates! Laura Dawson

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

Here's patient #2 from the REPAIR trial, the first one I've enrolled. These are the two individual plans, previous treatment on the left (5 years ago), new treatment on the right. 51% repair allowed at 5 years at this dose level.

It hit home as I returned to Sunnybrook Health Sciences Centre, where my own mother received cancer treatment with a message of HOPE to all who fight this disease. To help the more than 247,000 Canadians this year alone who will be diagnosed with cancer, I was proud to announce an ambitious plan to

Is observation SOC for adjuvant cholangio?

A new publication shows SBRT is more cost-effective, with a greater improvement in quality of life than surgery for stage I NSCLC. As usual, there are caveats with the analyses. ro-journal.biomedcentral.com/articles/10.11…

🌍Sep 7, 2025 marked the inaugural #WorldRadiotherapyAwarenessDay! Radiotherapy is vital in cancer care - curing, controlling & supporting patients worldwide. At Radiation Oncology, we’re proud to train future leaders & drive innovation in #RadiationOncology. 💙One Voice for #Radiotherapy

Honored to present today at #WCLC25 updated data from the Female Asian Nonsmoker Screening Study (FANSS) of baseline LDCT scan results in 1000 participants, largest screening study dedicated solely to a nonsmoking population. 1/3

🚨Biparametric MRI (no contrast) is noninferior to multiparametric MRI for detecting clinically significant #prostatecancer 🚨 📢 PRIME trial in JAMA ⭐️RCT of 490 patients w/ suspicion of prostate cancer ➡️ Shorter scans ➡️ Lower cost ➡️ Similar accuracy Potential

Dose to prostate (36.25/5) is too cool (PACE-B used 40/5 to prostate) Benign bounce is common in first 3y and that 8% of bb will trip Phoenix definition. I’d be willing to bet that with further FU, BF failure curves will cross But overall great study. Congrats‼️

Serious question: are thoracic surgeons elated or regretful after resecting a lobe or multiple lobes out of patients with a pCR? I can image it might be bitter-sweet learning the surgery could’ve been omitted. Jonathan Spicer MD PhD Stephen R Broderick MD MPHS

Excited to be at the inaugural Alberta Oncology Colloquium!

Looks incredible!

At the 20th Consortium meeting, it was inspiring to connect with so many members and see the progress being made in MRgRT. We're grateful to all who contributed their expertise and enthusiasm. Until next time!

Here are all the oligomets RCTs. HRs < 1 in green. Matthias Guckenberger